IP Library Granted Patent US 7,094,574
Granted Patent B2
US 7,094,574 · App. 11/123,362 · Granted Aug 22, 2006

Recombinant cell clones having increased stability and methods of making and using the same

Assignee: Baxter Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,094,574
App. No.
11/123,362
Granted
Aug 22, 2006
Kind
B2
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (17)

1. A method of producing a recombinant product under serum- and protein-free conditions on a large technical scale comprising the steps of:

providing an isolated, stable recombinant original cell clone, said original cell clone being stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product,

multiplying said original stable cell clone in serum- and protein-free medium so as to obtain a cell culture,

culturing said cell culture containing stable cells in a bioreactor, thereby obtaining said recombinant product, and

harvesting said recombinant product from a supernatant of said cell culture, wherein said serum- and protein-free medium comprises purified, ultrafiltrated soybean peptone having a molecular weight of ≦1000 Dalton.

2. A method as set forth in claim 1 , wherein said serum- and protein-free medium comprises purified, ultrafiltrated soybean peptone having a molecular weight of ≦500 Dalton.

3. A method as set forth in claim 1 , wherein said serum- and protein-free medium comprises purified, ultrafiltrated soybean peptone having a molecular weight of ≦350 Dalton.

4. A method as set forth in claim 1 , wherein the recombinant product is FVIII or a polypeptide having FVIII activity.

5. A method as set forth in claim 1 , wherein the recombinant product is vWF or a polypeptide having vWF activity.

6. A method as set forth in claim 1 , wherein the recombinant product is FVIII or a polypeptide having FVIII activity or vWF or a polypeptide having vWF activity.

7. A method for preparing a recombinant factor VIII protein or polypeptide having factor VIII activity from a mammalian cell culture wherein said mammalian cells have been transformed to express recombinant factor VIII, comprising the steps of:

multiplying a mammalian recombinant cell clone stable in serum- and protein-free medium, wherein purified, ultrafiltered soybean peptone is added to the medium, so as to obtain a cell culture,

culturing said cell culture containing stable cells in a bioreactor so as to obtain a cell culture, and

harvesting said recombinant polypeptide from a supernatant of said cell culture.

8. A recombinant mammalian cell clone stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product, wherein said recombinant product is FVIII or a polypeptide having FVIII activity.

9. A recombinant mammalian cell clone stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product, wherein said recombinant product is vWF or a polypeptide having vWF activity.

10. A recombinant mammalian cell clone stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product, wherein said recombinant product is FVIII or a polypeptide having FVIII activity or vWF or a polypeptide having vWF activity.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2015
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 036825/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 035424/0172 →
CHANGE OF NAME Recorded Mar 7, 2011
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 025914/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2006
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 017861/0919 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (4)
Continuation 1017066100 · Jun 12, 2002
Continuation 0932461200 · Jun 2, 1999
Continuation In Part 0910025300 · Jun 19, 1998
Related Publication 20050196843A1 · Sep 8, 2005